Navigation Links
Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis
Date:7/28/2010

HORSHAM, Pa., July 28 /PRNewswire/ -- Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

"The outcomes of the Phase III SAR trial validate the potential of BDP HFA as a treatment option for patients trying to manage their nasal allergies," said Mark Salyer, General Manager of Teva's Respiratory Division. "The goal of this development program is to address the unmet clinical need among the 60 million Americans affected with allergic rhinitis who are looking for a solution that delivers a 'dry' experience to avoid the 'wet feeling' and postnasal drip associated with the nasal spray formulations that are available today."

Currently, the intranasal spray (INS) market is composed only of aqueous or "wet feeling" products; however, prior to the U.S. Food and Drug Administration's (FDA) decision to phase out metered dose inhalers (MDIs) that contain chlorofluorocarbons (CFCs), the nasal market also included aerosol or "dry formulation" sprays. Teva's Nasal Aerosol utilizes an HFA propellant. Future studies will further examine the safety and efficacy profile of this product.

Based on results from the Phase I study that evaluated the pharmacokinetics, safety and tolerability of BDP HFA, the systemic exposure following administration of the treatment (up to 320 mcg/day) was approximately 27 percent of orally inhaled BDP HFA, which is marketed by Teva as the asthma treatment QVAR® (beclomethasone
'/>"/>

SOURCE Teva Respiratory, a subsidiary of Teva Pharmaceutical Industries Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
2. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
3. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
4. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
5. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
6. Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive
7. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
8. PARI Respiratory Launches PEP S
9. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
10. OxySure(R) Aids Student in School Respiratory Arrest: WFAA Channel 8 News
11. Reportlinker Adds Chinese Markets for Respiratory Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  Hologic, ... important cervical cancer screening study i published ... a peer-reviewed journal of the American Cancer Society. ... Diagnostics and the University of Pittsburgh Medical Center, supports current ... which recommend that women 30-65 years of age ...
(Date:4/16/2015)... April 16, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Tuesday, April 21, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
... today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.   , ... ... ... ...
... Inc. (Nasdaq: MITI ) announced today the closing of its previously announced underwritten public offering. Prior to closing, the ... sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 ... ... , , ...
Cached Medicine Technology:Actavis Receives Approval of Alprazolam ODT in the U.S. 2Actavis Receives Approval of Alprazolam ODT in the U.S. 3Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:4/17/2015)... (PRWEB) April 17, 2015 At the ... EcoLuxe Lounge and the “Salute to the Oscars” in ... Beverly Hilton Hotel, overlooking the impressive Los Angeles skyline. ... organized by Debbie Durkin, LA’s leading producer of sustainable ... many of the world’s premier providers of eco-friendly and ...
(Date:4/17/2015)... 17, 2015 Baptist Health and The ... a partnership agreement designed to transform oncology care in ... have agreed to create a joint cancer program to ... translational research. Baptist MD Anderson Cancer Center is anticipated ... single destination for highly coordinated, multidisciplinary cancer care for ...
(Date:4/17/2015)... The American College of Traditional Chinese Medicine (ACTCM) is ... April 29. The event will be held from 11 a.m. to ... St. in San Francisco, CA. , The agenda for the day ... DeHaro campus (room F), 11:10 a.m. – Introduction and welcome ... lunch with current students, faculty and staff, 1 p.m. – Observe ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post ... insurance quotes . , The online environment can ... cars. Drivers should always compare multiple car insurance policies ... is a competitive one, which means that customers can ... It is now possible to compare online car insurance ...
(Date:4/17/2015)... released a new blog post explaining the dangers of sleeping ... rates . , Falling asleep at the wheel can ... impact on auto insurance prices. The premiums will go up ... newly released blog post talks more about drowsiness at the ... is now possible to find low cost car insurance plans ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2
... help avoid treatment toxicity, research shows , WEDNESDAY, Sept. ... researchers may have found a better way for them ... , A regimen using antibodies instead of high-dose ... to Dr. Persis J. Amrolia, a doctor in the ...
... , ROCHESTER, N.Y., Sept. 2 "Everyone ... flu virus. Let me tell you about my personal encounter ... article on Dr. Hanan Polansky,s book, where he describes his ... After I read the article, I started taking Gene-Eden, a ...
... Agreement to Sell MDS Analytical Technologies to Danaher, ... Shareholders;, Announces Intent to Sell MDS Pharma Services, ... MDS; NYSE: MDZ ), a leading provider of products ... it has entered into an agreement to sell its MDS Analytical ...
... , , ... (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, ... and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both ... for calcitriol softgel capsules and oral liquid were $70 million (IMS ...
... , THE WOODLANDS, Texas, Sept. 2 ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... Sands, M.D., Ph.D. , Lexicon,s president and chief executive officer, ... Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 9, 2009 ...
... ... bill compliance auditing, today announced their partnership with Pat Palmer, President and Founder of ... of whom are pioneers in the field of medical bill advocacy. , ... Boca Raton, FL (PRWEB) September ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement' 2Health News:MDS Announces Strategic Repositioning 2Health News:MDS Announces Strategic Repositioning 3Health News:MDS Announces Strategic Repositioning 4Health News:MDS Announces Strategic Repositioning 5Health News:MDS Announces Strategic Repositioning 6Health News:MDS Announces Strategic Repositioning 7Health News:MDS Announces Strategic Repositioning 8Health News:MDS Announces Strategic Repositioning 9Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: